Pfizer Says It Completed Acquisition of Seagen; Deal Completed At $229 In Cash Per Share Of Seagen For a Total Enterprise Value Of Approximately $43B
Portfolio Pulse from Benzinga Newsdesk
Pfizer has completed the acquisition of Seagen at $229 per share, with a total enterprise value of approximately $43 billion.
December 14, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer's acquisition of Seagen could potentially enhance its oncology portfolio and create long-term value, but may have short-term financial impacts due to the cost of the acquisition.
While the acquisition of Seagen is a strategic move for Pfizer to strengthen its position in the oncology market, the immediate financial burden of the $43 billion deal could weigh on Pfizer's short-term financial performance. However, the market may have already priced in the acquisition news, leading to a neutral short-term impact on Pfizer's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Seagen has been acquired by Pfizer at $229 per share, which will result in the delisting of Seagen's stock.
Seagen's acquisition by Pfizer at $229 per share is a definitive action that will lead to the delisting of Seagen's stock. Shareholders of Seagen will receive a cash payout, and the stock will no longer be traded, which is a positive outcome for Seagen's investors who will receive a premium on their shares.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100